int230-6
·Code: INT230-6
int230-6: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| INTENSITY THERAPEUTICS, INC. (INTS) | Phase 3 |
Clinical Trials (1)
A Multicenter, Randomized, Phase 3 Study to Assess the Efficacy and Safety of INtratumorally Administered INT230-6 (SHAO, VINblastine, CIsplatin) Compared With US Standard of Care in Adults With Locally Recurrent, InoperaBLE, or Metastatic Soft Tissue Sarcomas (INVINCIBLE-3)
Frequently asked questions
Who is developing int230-6?
int230-6 is being developed by INTENSITY THERAPEUTICS, INC..
How many clinical trials involve int230-6?
BioSniper tracks 1 clinical trial involving int230-6.
Get deeper analysis on int230-6
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis